Experimental and Human Evidence for Lipocalin‐2 (Neutrophil Gelatinase‐Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and Heart Failure

Experimental and Human Evidence for Lipocalin‐2 (Neutrophil Gelatinase‐Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and Heart Failure

BackgroundCardiac hypertrophy increases the risk of developing heart failure and cardiovascular death. The neutrophil inflammatory protein, lipocalin‐2 (LCN2/NGAL), is elevated in certain forms of cardiac hypertrophy and acute heart failure. However, a specific role for LCN2 in predisposition and et...

Full description

Bibliographic Details
Main Authors: Francine Z. Marques, Priscilla R. Prestes, Sean G. Byars, Scott C. Ritchie, Peter Würtz, Sheila K. Patel, Scott A. Booth, Indrajeetsinh Rana, Yosuke Minoda, Stuart P. Berzins, Claire L. Curl, James R. Bell, Bryan Wai, Piyush M. Srivastava, Antti J. Kangas, Pasi Soininen, Saku Ruohonen, Mika Kähönen, Terho Lehtimäki, Emma Raitoharju, Aki Havulinna, Markus Perola, Olli Raitakari, Veikko Salomaa, Mika Ala‐Korpela, Johannes Kettunen, Maree McGlynn, Jason Kelly, Mary E. Wlodek, Paul A. Lewandowski, Lea M. Delbridge, Louise M. Burrell, Michael Inouye, Stephen B. Harrap, Fadi J. Charchar
Format: Article
Language:English
Published: Wiley 2017-11-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
concentric hypertrophy
C‐reactive protein
gene coexpression networks
GlycA
hypertrophy
lipocalin‐2
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.117.005971

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.117.005971

Similar Items